Premium
Amyloid beta regulates ER exit sites formation through O‐GlcNAcylation triggered by disrupted calcium homeostasis
Author(s) -
Cho Hyun Jin,
MookJung Inhee
Publication year - 2020
Publication title -
biology of the cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 85
eISSN - 1768-322X
pISSN - 0248-4900
DOI - 10.1111/boc.201900062
Subject(s) - copii , microbiology and biotechnology , golgi apparatus , biology , vesicle , calcium , copi , homeostasis , calcium metabolism , endoplasmic reticulum , secretory pathway , biochemistry , medicine , membrane
Background Information Aberrant production of amyloid beta (Aβ) causes disruption of intracellular calcium homeostasis, a crucial factor in the pathogenesis of Alzheimer's disease. Calcium is required for the fusion and trafficking of vesicles. Previously, we demonstrated that Sec31A, a main component for coat protein complex II (COPII) vesicles at ER exit sites (ERES), is modulated by O‐GlcNAcylation. O‐GlcNAcylation, a unique and dynamic protein glycosylation process, modulates the formation of COPII vesicles. Results In this study, we observed that disrupted calcium levels affected the formation of COPII vesicles in ERES through calcium‐triggered O‐GlcNAcylation of Sec31A. Additionally, we found that Aβ impaired ERES through Aβ‐disturbed calcium homeostasis and O‐GlcNAcylation of Sec31A in neuronal cells. Furthermore, we identified that Aβ disrupted the ribbon‐like structure of Golgi. Golgi fragmentation by Aβ was rescued by up‐regulation of O‐GlcNAcylaion levels using Thiamet G (ThiG), an O‐GlcNAcase inhibitor. Additionally, we observed that the Golgi reassembly stacking proteins having a function in Golgi stacking showed attenuation at COPII vesicles following Aβ treatment. Conclusions This study demonstrated that Aβ impaired Sec31A targeting to ERES through altered Sec31A O‐GlcNAcylation triggered by disruption of intracellular calcium homeostasis. Significance The findings of this study suggested that protection of ERES or Sec31 O‐GlcNAcylation may offer a promising novel avenue for development of AD therapeutics.